

Information Regarding Clinical Trial

Title	A Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients who have advanced solid tumors with mutations or gene expression abnormalities predictive of response to one of these agents.
Protocol Number	ML28897-PRO02
Sponsor	Genentech
Investigator	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
Study Related Phone Numbers	479-587-1700 (24 hours)
Key Points for Study	Solid Tumor NO Hem. Malignancy HER2 overexpression, amplification, or HER2-activating Mutation OR EGFR positive OR BRAF positive OR Hedgehog pathway No previous treatment with a drug that targets the above pathways No other trial or standard treatment available for the patient